NSE: CIPLA | BSE: 500087

Mid-range Performer

Download real time

1532.50 44.60 (3.00%)

5.5M NSE+BSE Volume

High volume today

NSE 25 Jul, 2025 3:31 PM (IST)

123,787.9

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Estimates Beat

Cipla's Q1 net profit beats Forecaster estimates by 7.4%, EBITDA margin falls slightly by 7 bps YoY See details

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Search Inside the pdf :

Cipla Ltd.

14 May 2025

1532.50

3.00%

Cipla (CIPLA IN) Q4FY25 Result Update In-line EBITDA;...

Buy: Cipla Ltd.

Prabhudas Lilladhar

CIPLA's Q4FY25 EBITDA (Rs15.4bn; 22.8% OPM) was in line with our estimates. While Q4 is seasonally weak quarter; margins at 23% were above our estimate. Despite delay in new launches and supply issues of gLanreotide; Cipla managed to deliver strong profitability/margins in H2FY25. We expect Cipla to maintain its existing US sales run-rate. This will be aided by several high value niche launches in the US like gAbraxane, Nilotininb, gAdvair. Further, Cipla's...

Cipla Ltd.'s price crossed above 200Day SMA today

Cipla Ltd.

11 Apr 2025

1532.50

3.00%

Cipla (CIPLA IN) Event Update Gets approval for...

Buy: Cipla Ltd.

Prabhudas Lilladhar

Cipla has secured its much awaited USFDA approval of gAbraxane following Change in Estimates | Target | Reco the Goa facility clearance in November 2024, milestone that reinforces our positive stance on the company. Our FY26E and FY27E EPS factors in...

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

29 Jan 2025

1532.50

3.00%

CIPLA LTD.

Buy: Cipla Ltd.

Prabhudas Lilladhar

Cipla Ltd.'s price crossed above 30Day SMA today

Cipla Ltd.

29 Jan 2025

1532.50

3.00%

Result Update:Cipla

Buy: Cipla Ltd.

Axis Direct

We maintain our BUY recommendation with a target price of Rs 1,700/share.

Cipla Ltd.'s price crossed above 30Day SMA today

Cipla Ltd.

28 Jan 2025

1532.50

3.00%

3Q results beat estimates; yet to scale up Lanreotide supply

Neutral: Cipla Ltd.

Recommendation Target

Motilal Oswal

CIPLA delivered better-than-expected 3QFY25 earnings. While revenue was in line, EBITDA/adj. PAT beat our estimates, aided by a better product mix and lower R&D spending.

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

17 Jan 2025

1532.50

3.00%

Empowering health, Enriching Lives

Accumulate: Cipla Ltd.

Asit C Mehta Investment Interrmediates

Cipla's "Future Fit" strategy outlines ambitious growth objectives, including becoming India’s 2nd largest pharmaceutical company, leading South Africa’s prescription and OTC markets, ranking 2nd in U.S. respiratory generics, and doubling international revenue.